Chronic use of benzodiazepines: The problem that persists

Int J Psychiatry Med. 2023 Sep;58(5):426-432. doi: 10.1177/00912174231166252. Epub 2023 Mar 27.

Abstract

Though clinical guidelines and policies discourage the chronic prescribing of benzodiazepines, rates of prescribing have continued to rise in the United States with an estimated 65.9 million office visits per year made for this purpose. Quietly, we have become a nation on benzodiazepines. There are numerous reasons for this discrepancy between official recommendations on the one hand, and actual clinical practice on the other. Drawing from the literature, we argue that while patients and providers both shoulder some of the responsibility, they cannot be solely blamed. Rather, policies and guidelines regarding benzodiazepine prescribing have become out of touch with the clinical reality that benzodiazepines are now deeply entrenched in modern medicine. We propose that guidelines regarding benzodiazepines need to reconsider how to apply concepts such as harm reduction and other lessons learned in the opioid epidemic in order to help physicians manage this increasingly pressing problem affecting millions of Americans.

Keywords: Benzodiazepines; deprescribing; sedative-hypnotic use disorder.

Publication types

  • Review

MeSH terms

  • Analgesics, Opioid / therapeutic use
  • Benzodiazepines* / adverse effects
  • Drug Prescriptions*
  • Humans
  • Practice Patterns, Physicians'
  • United States / epidemiology

Substances

  • Benzodiazepines
  • Analgesics, Opioid